image credit: Freepik

CureVac giving up on first COVID mRNA vax, focusing on GSK-partnered 2nd attempt

October 12, 2021


With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year and switching focus to a second mRNA asset with GlaxoSmithKline.

A lot was expected from the little German biotech CureVac, with an mRNA shot on its hands, many were hoping the vaccine could match the heights seen by fellow/rival native BioNTech. But a botched first attempt that saw an efficacy range below 50%—far below the original 90% seen in early mRNA readouts from others—has pushed CureVac to finally toss that vaccine out.

Read More on FierceBiotech